Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Mexico
  4. Mexican Stock Exchange
  5. Genomma Lab Internacional, S.A.B. de C.V.
  6. News
  7. Summary
    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

(LAB B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genomma Lab Internacional B de C : External Auditor Ratification

08/04/2021 | 07:06pm EDT

Investor Relations

T. +52 (55) 5081 0000

Investor.relations@genommalab.com

GENOMMA LAB INTERNACIONAL RATIFIES INDEPENDENT AUDITOR

Mexico City, August 4, 2021 - Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announced that at the Company's July 27, 2021 Board meeting its Board of Directors ratified the appointment of Galaz, Yamazaki, Ruiz Urquiza, S.C., Member of Deloitte Touche Tohmatsu Limited, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.

Therefore, Genomma hereby submits a certified copy by the Company's Board of Directors' independent secretary related to the above resolution in compliance with article 17 of the CNBV "Circular Única de Auditores."

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a lowcost, highly flexible supply chain operating model. For more information visit: www.genommalab.com

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

https://inversionistas.genommalab.com

1

EXTRACTO DE LAS RESOLUCIONES UNÁNIMES ADOPTADAS FUERA SESION POR LA TOTALIDAD DE LOS MIEMBROS DEL CONSEJO DE ADMINISTRACIÓN DE GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. ADOPTADAS EL 27 DE JULIO DE 2021.

RESOLUCIÓN CUARTA

[…]

Adicionalmente, con la opinión favorable del Comité de Auditoría y Prácticas Societarias y con fundamento en lo dispuesto en el artículo 16 de las Disposiciones de carácter general aplicables a las entidades y emisoras supervisadas por la Comisión Nacional Bancaria y de Valores que contraten servicios de auditoría externa de estados financieros básicos, se aprueba:

  1. La ratificación del despacho Galaz, Yamazaki, Ruiz Urquiza, S.C. para que realice la auditoría de los estados financieros consolidados de la Sociedad correspondientes al ejercicio social 2021; y
  2. La ratificación y/o designación, según sea el caso, de los despachos externos mencionados en el "Anexo 1" de estas resoluciones, para que realicen la auditoría de los estados financieros individuales de las principales subsidiarias de la Sociedad que en dicho anexo se mencionan.

[…]

-O-

El suscrito, Secretario no miembro del Consejo de Administración de Genomma Lab Internacional, S.A.B. de C.V. (la "Sociedad"), hago constar que esta transcripción es un extracto fiel, en su parte conducente, de las resoluciones unánimes adoptadas fuera Sesión por la totalidad de los miembros del Consejo de Administración de Genomma Lab internacional, S.A.B. de C.V. adoptadas el 27 de julio de 2021.

Ciudad de México, México, a 03 de agosto de 2021.

______________________________________________

Lic. Efraín Tapia Córdova

Secretario no miembro del Consejo de Administración

Genomma Lab Internacional, S.A.B. de C.V.

Disclaimer

Genomma Lab International SAB de CV published this content on 04 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2021 23:05:03 UTC.


ę Publicnow 2021
All news about GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
10/14GENOMMA LAB INTERNACIONAL B DE C : 3Q-2021 Earnings Call Advisory
PU
09/07GENOMMA LAB INTERNACIONAL B DE C : Receives Good Manufacturing Practices (GMP) Certificati..
PU
08/04GENOMMA LAB INTERNACIONAL B DE C : External Auditor Ratification
PU
07/28GENOMMA LAB INTERNACIONAL B DE C : Q2 2021 Earnings Release
PU
07/28Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Second Quart..
CI
07/28TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
07/13GENOMMA LAB INTERNACIONAL B DE C : 2Q-2021 Earnings Call Advisory
PU
04/28TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
04/28Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the First Quarte..
CI
02/24TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
More news
Financials
Sales 2021 14 736 M 724 M 724 M
Net income 2021 1 616 M 79,4 M 79,4 M
Net Debt 2021 3 693 M 182 M 182 M
P/E ratio 2021 12,7x
Yield 2021 1,46%
Capitalization 19 618 M 959 M 964 M
EV / Sales 2021 1,58x
EV / Sales 2022 1,40x
Nbr of Employees 1 451
Free-Float 70,9%
Chart GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Duration : Period :
Genomma Lab Internacional, S.A.B. de C.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 19,46 MXN
Average target price 26,08 MXN
Spread / Average Target 34,0%
EPS Revisions
Managers and Directors
Jorge Luis Brake Valderrama Chief Executive Officer
Antonio Zamora Galland Vice President-Administration & Finance
Rodrigo Alonso Herrera Aspra Chairman
Marco Sparvieri Chief Operating Officer & Executive Vice President
Juan Alonso Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.3.29%959
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657